GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Royalty Pharma RPRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

68.77

+2.18%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Royalty Pharma annual report

Filed with the US Securities and Exchange Commission

10-K

The latest annual report covers the year to 31 Dec 2025, filed on 11 Feb 2026.

Read the 10-K on SEC.gov ↗

Five-year highlights

In USD.

FY2025FY2024FY2023FY2022FY2021
Revenue$2.38bn$2.26bn$2.35bn$2.24bn$2.29bn
Operating income$1.56bn$1.29bn$1.61bn$307.1m$1.43bn
Net income$770.9m$859.0m$1.13bn$42.8m$619.7m
Free cash flow$2.49bn$2.77bn$872.3m$102.8m$2.02bn
Total assets$19.62bn$18.22bn$16.38bn$16.81bn$17.52bn
Shareholders' equity$6.48bn$6.95bn$6.53bn$5.63bn$10.25bn

Revenue by business

Year to 31 Dec 2025

  • Income from financial royalty assets $2.26bn · 95.1%
  • Other royalty income and revenues $117.0m · 4.9%

Filings

Newest first, from SEC EDGAR

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.